BRD4 and leukemia: IPs with anti-BRD4 antibody and co-IP with antibodies against various components of the active RNA-pol-II and RCMT complexes demonstrated an ~80-fold increase in BRD4-associated RNA-pol-II CTD-S2P in the 5-AZA-resistant M2AR leukaemia cells compared to the 5-AZA-sensitive OCI-M2 cells (Fig. 6d), but no increase in the BRD4-bound CDK9/P-TEFb was observed in the 5-AZA-resistant M2AR cells.